Nystatin Unsuitable for Invasive Candidiasis in Neutropenic Patients
The question asks to identify the drug not recommended for treating invasive candidiasis specifically in neutropenic patients. Neutropenic patients have a very low white blood cell count, making them highly susceptible to severe infections.
Understanding Antifungal Therapy Choices
For invasive fungal infections like invasive candidiasis, the chosen antifungal must be effective systemically (throughout the body). Let's analyze the options:
- Amphotericin-B: A potent antifungal agent effective against a broad spectrum of fungi, including Candida species. It is commonly used for invasive candidiasis.
- Caspofungin: An echinocandin antifungal drug. It disrupts the fungal cell wall and is a recommended treatment option for invasive candidiasis, including in neutropenic patients.
- Voriconazole: A broad-spectrum triazole antifungal. It is effective systemically and is a key treatment option for various invasive fungal infections, including invasive candidiasis.
- Nystatin: This antifungal is primarily used topically for superficial Candida infections (e.g., oral thrush, vaginal candidiasis). It has very poor gastrointestinal absorption and is not suitable for treating systemic or invasive infections.
Rationale for Nystatin Exclusion
Nystatin's lack of systemic absorption means it cannot reach the site of an invasive infection within the body. Therefore, it is ineffective and not recommended for treating invasive candidiasis, particularly in vulnerable neutropenic patients who require aggressive systemic therapy.
The recommended treatments for invasive candidiasis in neutropenic patients are systemic antifungals like Amphotericin-B, Caspofungin, or Voriconazole, depending on the specific situation and susceptibility patterns.
Important Questions from Fungal Infections
- Which of the following opportunistic systemic mycoses is characterized by rapid development of severe tissue necrosis and emerged as specific complication associated with COVID-19 infection in India?
- Which of the following fungal infections is caused by dermal inoculation of the fungal agent, usually from a thorn?
Consider the following statements with regard to coccidioidomycosis:
1. It is a primary systemic mycosis caused by dimorphic fungi Cocci- dioides immitis and Coccidioides posadasii.
2. Primary pulmonary coccidioido- mycosis presents with cough, fever, chest pain and arthritis.
3. Progressive pulmonary coccidioido- mycosis presents with constitu- tional symptoms like fever, weight loss, anorexia and features of lobar pneumonia.
4. Coccidioides meningitis is a mild disease, not warranting any treatment.
Which of the statements given above are correct?
- A patient receiving chemotherapy develops neutropenia. He presents with fever, cough, expectoration, chest pain and hemoptysis. His CT scan of chest reveals nodular infiltrates with halo sign and crescent sign. The most useful drug for treating him is
- Consider the following statements with regard to Amphotericin B :
1. It is a narrow spectrum antifungal agent.
2. It can cause nephrotoxicity.
3. It lacks an oral preparation.
4. Its lipid formulations are less toxic.
Select the correct answer using the code given below:
